68Ga-FAPI PET/MRI scan for liver cancer diagnosis
Part of Cancer, Digestive system clinical trials.
This trial studies how well a special imaging test (68Ga-FAPI PET/MRI) can detect and evaluate hepatocellular carcinoma (HCC), a type of liver cancer. It may help doctors confirm diagnosis and plan next steps by seeing how the cancer takes up the tracer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 21 and 99 years old
- You have confirmed liver cancer (HCC) by tissue testing or standard imaging rules
- You have not had local procedures or treatments targeted to the liver cancer yet
- Your kidney function is enough for the scan (creatinine clearance over 30 ml/min)
- You can sign informed consent
- You cannot be allergic to the 68Ga-FAPI tracer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well special imaging scans (PET/CT or PET/MRI) work in adults with suspected or diagnosed liver cancer. It may help doctors better see the cancer and plan next steps.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This study tests whether a new type of PET/CT scan can measure liver scarring (fibrosis) in people with fatty liver disease. It might help doctors check liver damage without needing repeated biopsies.
This trial is testing a new type of PET scan (called 68Ga-FAPI) to see if it can better detect biliary tract cancers, including advanced or recurring gallbladder cancer and intrahepatic cholangiocarcinoma. It may help doctors find cancer more accurately, which could guide better treatment decisions.
This trial tests a new PET/CT scan that uses a special tracer (68Ga-FAPI-Biotin) to help detect and see various solid tumors. It may provide more detailed images to guide treatment decisions.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.